Leah Kuntz

Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.

Badr Ratnakaran, MBBs, highlights the rising stressors for older adults, emphasizing the urgent need for improved health care and support systems.

The APA Annual Meeting: a valuable career opportunity.

At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.

Mena Mirhom, MD, the Psychiatric Times Media & Psychiatry Section Editor, discusses media training for psychiatry fellows, enhancing their skills to effectively communicate and combat misinformation.

Ramaswamy Viswanathan, MD, DrMedSc, emphasizes the vital role of lifestyle in mental health treatment and advocates for holistic approaches to prevent premature death at the 2025 APA Annual Meeting.

Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.

Resilience: how does it improve overall health? Helen Lavretsky, MD, shared her thoughts at the 2025 APA Annual Meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Our board members are presenting at this year's APA Annual Meeting. Be sure to check out their sessions!

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

Badr Ratnakaran, MBBS, Psychiatric Times' new Climate Change Section Editor, explores the intersection of climate change and mental health, highlighting the urgent need for awareness and support in clinical practice.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Stay informed with this week's highlights, including more on dementia prevention, a treatment for alcohol use disorder, National Nurses Week, and finding joy.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

Stay informed with this week's highlights, including more on deep brain stimulation, innovative assessments for borderline personality disorder, and athlete mental health research.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Explore the evolving role of psychotherapy in psychiatry in our May theme! We want to hear about your insights, tips, and case studies.

Check out the pipeline updates from April!

2025: a big year for emergency psychiatry. Don't miss any of our Special Report articles!

A groundbreaking study explores innovative neuroassessment technology to enhance understanding and treatment of borderline personality disorder symptoms.

Stay informed with this week's highlights in psychiatric advancements, including emergency psychiatry, a major update on Cobenfy, new partnerships for better treatments, and more.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

Explore key updates in psychiatric health, including Black maternal health, self-harm insights, schizophrenia treatment advancements, and expert interviews.